These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24079759)

  • 1. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
    Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
    Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
    Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
    Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
    Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
    BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.
    Lee HW; Choe M
    Pathol Int; 2012 Nov; 62(11):735-41. PubMed ID: 23121604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
    Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H
    Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance].
    Wang G; Qin W; Zheng J; Wei M; Zhou X; Wang H; Wen W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):82-4, 88. PubMed ID: 23294722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic role of immunohistochemical expression of napsin-A aspartic peptidase in clear cell and papillary renal cell carcinoma: a study including 233 primary and metastatic cases.
    Xu B; Abourbih S; Sircar K; Kassouf W; Aprikian A; Tanguay S; Brimo F
    Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):206-12. PubMed ID: 23702650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
    Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
    J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
    Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
    Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.
    Wagener N; Macher-Goeppinger S; Pritsch M; Hüsing J; Hoppe-Seyler K; Schirmacher P; Pfitzenmaier J; Haferkamp A; Hoppe-Seyler F; Hohenfellner M
    BMC Cancer; 2010 Oct; 10():524. PubMed ID: 20920340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
    Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
    J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
    Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
    Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
    Sakurai T; Bilim VN; Ugolkov AV; Yuuki K; Tsukigi M; Motoyama T; Tomita Y
    Biochem Biophys Res Commun; 2012 Jun; 422(4):607-14. PubMed ID: 22609199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205.
    Hirata H; Hinoda Y; Shahryari V; Deng G; Nakajima K; Tabatabai ZL; Ishii N; Dahiya R
    Cancer Res; 2015 Apr; 75(7):1322-31. PubMed ID: 25600645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not.
    Findeis-Hosey JJ; Huang J; Li F; Yang Q; McMahon LA; Xu H
    Hum Pathol; 2011 Jun; 42(6):867-72. PubMed ID: 21292308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
    Eichenauer T; Simmendinger L; Fraune C; Mandelkow T; Blessin NC; Kluth M; Hube-Magg C; Möller K; Clauditz T; Weidemann S; Dahlem R; Fisch M; Riechardt S; Simon R; Sauter G; Büscheck F; Rink M
    World J Urol; 2021 Feb; 39(2):481-490. PubMed ID: 32303902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.